Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

被引：0

作者：

Liegeon, Geoffroy ^{[1
]}

Kaperak, Christopher ^{[1
]}

Friedman, Eleanor E. ^{[1
]}

Djuricich, Paul ^{[2
]}

Dawdani, Alicia ^{[1
]}

Stafford, Kane ^{[2
]}

Plotkin, Sophie ^{[1
]}

Schmitt, Jessica ^{[1
]}

Hazra, Aniruddha ^{[1
]}

Christopoulos, Katerina A. ^{[3
]}

Schneider, John A. ^{[1
]}

Mcnulty, Moira C. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Chicago, IL USA

[2] Univ Chicago, Dept Pharm, Chicago, IL USA

[3] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 03期

基金：

美国国家卫生研究院;

关键词：

cabotegravir; injectable; long-acting; people with HIV; rilpivirine; PROGRAM; CARE;

D O I：

10.1093/ofid/ofaf094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

引用

页数：7

共 50 条

[21] Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection
Zeuli, John D.
Rivera, Christina G.
Smith, Bradley L.
Otto, Ashley
Temesgen, Zelalem
DRUGS OF TODAY, 2022, 58 (12) : 555 - 576
[22] Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine
Hill, Lucas A.
Abulhosn, Kari K.
Yin, Jeffrey F.
Bamford, Laura P.
AIDS, 2023, 37 (04) : 605 - 609
[23] Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis
Durham, Spencer H.
Milam, Ashlee
Waer, Dylan
Chahine, Elias B.
ANNALS OF PHARMACOTHERAPY, 2023, 57 (03) : 306 - 316
[24] Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection
Durham, Spencer H.
Chahine, Elias B.
ANNALS OF PHARMACOTHERAPY, 2021, 55 (11) : 1397 - 1409
[25] Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
Atoyebi, Shakir
Bunglawala, Fazila
Cottura, Nicolas
Granana-Castillo, Sandra
Montanha, Maiara Camotti
Olagunju, Adeniyi
Siccardi, Marco
Waitt, Catriona
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
[26] Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: Results from the Dutch ATHENA national observational cohort
Jongen, V.
Wit, F.
van Eeden, A.
Brouwer, A.
Soetekouw, R.
El Moussaoui, R.
Stalenhoef, J.
Sigaloff, K.
Mudrikova, T.
Gisolf, J.
Wensing, A.
van der Valk, M.
HIV MEDICINE, 2023, 24 : 167 - 169
[27] Expanded Insights From a Case Study on Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnancy
Ziemba, Lauren
Ketchum, Rachel
Brummel, Sean
CLINICAL INFECTIOUS DISEASES, 2025,
[28] Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman Living With Human Immunodeficiency Virus
van der Wekken-Pas, Lena
Weiss, Fabian
Simon-Zuber, Charlotte
Sebisch, Rena
Wiese, Carmen
van Leeuwen, Elisabeth
Burger, David
Colbers, Angela
CLINICAL INFECTIOUS DISEASES, 2024, 79 (06) : 1468 - 1471
[29] Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China
Li, Mengqing
Guan, Hongjing
Zhong, Mingli
Di, Xiaoyun
Yu, Nawei
Chen, Chen
Cai, Rentian
Wei, Hongxia
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2025, 41 (02) : 107 - 112
[30] Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed
Hickey, Matthew D.
Grochowski, Janet
Mayorga-Munoz, Francis
Oskarsson, Jon
Imbert, Elizabeth
Spinelli, Matthew
Szumowski, John D.
Appa, Ayesha
Koester, Kimberly
Dauria, Emily F.
Mcnulty, Moira
Colasanti, Jonathan
Havlir, Diane V.
Gandhi, Monica
Christopoulos, Katerina A.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (03) : 280 - 289

← 1 2 3 4 5 →